+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free

LMWH is the Dominant Heparin Product Market in Europe and is Expected to Reach USD 3.14 Billion in 2022

Posted on Jun 21, 2015

Ultra low molecular weight heparin (ULMWHs) Market, low molecular weight heparin (LMWHs) Market, unfractionated heparin Market, anticoagulants Market.According to a new market report published by Transparency Market Research Heparin Market - Europe Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2022”, the Europe heparin market was valued at USD 2,004.5 million in 2013 and is expected to grow at a CAGR of 5.2% from 2014 to 2022, to reach an estimated value of USD 3,148.0 million in 2022.

 

Browse the full Heparin Market (Unfractionated Heparin, Low Molecular Weight Heparin & Ultra Low Molecular Weight Heparin) - Europe Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022 report at http://www.transparencymarketresearch.com/europe-heparin-market.html

 

Heparin is a highly sulfated glycosaminoglycan sourced from animals, and used as an anticoagulant therapy in patients with blood clots and those undergoing surgery and dialysis. Heparin is generally available as an injection which need to be administered in presence of a healthcare practitioner. Its dosage depends on the medical condition of the patient, drug response and type of heparin. There are three types of heparin available in the European market namely unfractionated heparin, low molecular weight heparin (LMWH) and ultra-low molecular weight heparin (ULMWH). Low molecular weight heparin is the majorly used heparin type in Europe owing to its added advantage over unfractionated heparin. Low molecular weight heparins such as enoxaparin, dalteparin, tinzaparin and certoparin are the majorly sold heparin drugs in Europe. 

 

europe-heparin-market

 

 

Unfractionated heparin is mainly used in hospitals and owing to its narrow therapeutic window and the possible risk of bleeding. Although, the effect of unfractionated heparin can be reversed using protamine sulphate, its use is diminishing owing to higher risk of osteopenia and thrombocytopenia. Therefore, researchers developed low molecular weight heparin which has lesser side effects and much safer compared to unfractionated heparin. Advent of low molecular weight heparin has decreased the market share of unfractionated heparin in Europe to less than 10% in 2013. Lovenox (enoxaparin) is a major brand in the LWMH market in Europe.

 

Further the advent of ultra-low molecular weight heparin in the European market has increased the market size of heparin products in this region. Arixtra (fondaparinux sodium) form GlaxoSmithKline plc is the major brand in Europe ULMWH market. Recently in 2012, Dr. Reddy’s Laboratory Ltd. had filed for marketing approval of its biosimilar version of Arxitra in Europe which was refiled in 2013 post receipt of comments for the European regulatory authorities. Entry of biosimilars will augment the market growth in Europe. However, concerns pertaining to the quality of heparin post the contamination issue in 2008 has alerted the regulatory authorities in Europe emphasizing on the traceability of raw heparin. This factor has delayed the market entry for biosimilar heparins in the European market. Presence of many LMWH product makes it the dominant product segment in the European heparin market. Moreover, LMWH will grow at a faster CAGR of 5.6% during the forecast period owing to it high demand and cost effective therapeutic performance compared to other heparins.

 

The Europe Heparin Market is segmented into the following categories: 

 

Europe Heparin Market, by Product

  • Unfractionated Heparin
  • Low Molecular Weight Heparin (LMWHs)
  • Ultra-low Molecular Weight Heparin (ULMWHs)

Europe Heparin Market, by Country

  • United Kingdom
    • Unfractionated Heparin
    • Low Molecular Weight Heparin (LMWHs)
    • Ultra-low Molecular Weight Heparin (ULMWHs)
  • Germany
    • Unfractionated Heparin
    • Low Molecular Weight Heparin (LMWHs)
    • Ultra-low Molecular Weight Heparin (ULMWHs)
  • France
    • Unfractionated Heparin
    • Low Molecular Weight Heparin (LMWHs)
    • Ultra-low Molecular Weight Heparin (ULMWHs)
  • Spain
    • Unfractionated Heparin
    • Low Molecular Weight Heparin (LMWHs)
    • Ultra-low Molecular Weight Heparin (ULMWHs)
  • Italy
    • Unfractionated Heparin
    • Low Molecular Weight Heparin (LMWHs)
    • Ultra-low Molecular Weight Heparin (ULMWHs)
  • Rest of the Europe
    • Unfractionated Heparin
    • Low Molecular Weight Heparin (LMWHs)
    • Ultra-low Molecular Weight Heparin (ULMWHs)

Browse : Our new press releases http://www.transparencymarketresearch.com/pressrelease/europe-heparin-industry.htm

 

About Us

 

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. 

 

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

 

Contact

 

Mr.Sudip S
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com